Submit offer Value-Based Care Market Access Strategy

Template for the Task Description
  
A good Task Description must include the following:  
 
1. GENERAL INFORMATION: 
Titel of tender: Value-Based Care Market Access Strategy
Your company’s name:  MultiBiopsy
Address:  Universitetsbyen 76, 8000 Aarhus C, Denmark

CVR nr.:  44304554
Date:  28.04.2026
Deadline for tender:  26.05.2026
For further questions, contact info:  William Ludvigsen, CEO
Upload of tender info: USe link in task description
Phone and e-mail:  William.Ludvigsen@multibiopsy.com 
tlf: +45 40106428
 
2. PRESENTATION OF COMPANY: 

MultiBiopsy is a Danish early-stage MedTech company developing an innovative biopsy device for soft-tissue cancer diagnostics. The company is developing a biopsy pistol capable of retrieving multiple tissue samples from a single insertion, with the aim of improving diagnostic accuracy, lowering complication risk, reducing re-biopsy rates, and fitting naturally into current interventional radiology workflows.

The company combines clinical, engineering, and regulatory competences and has already developed a proof-of-concept needle system together with external manufacturing and development partners. MultiBiopsy is currently focused on maturing the technology, strengthening its documentation package, and preparing a robust market access and regulatory pathway for future commercialization.

 
3. DESCRIPTION OF THE TASK UNDER MARKET EVALUATION: 

MultiBiopsy seeks a consultant with strong experience in a value-based care strategy, US MedTech market access, and provider-side economic adoption logic to help the company understand how its device may fit into value-based care models.

The task concerns both capability building and strategic clarification. MultiBiopsy wants to understand whether the device's expected benefits - including fewer complications, fewer re-biopsies, shorter procedure time, improved workflow, and faster diagnostic clarification - can support a value-based care positioning in addition to, or instead of, a traditional reimbursement-led access strategy.

The consultant is expected not only to assess this opportunity, but also to educate the MultiBiopsy team in how to approach value-based care analysis in practice. This includes teaching the company how to research, assess, document, plan, and build a value-based care plan and strategy, so MultiBiopsy can carry out substantial parts of this work independently in the future.

The task should therefore combine strategic analysis with competence transfer and practical guidance. The consultant is expected to:

•             Assess how MultiBiopsy's clinical, operational, and economic value proposition may align with value-based care models, provider incentives, and risk-sharing logic. 

•             Explain how value-based care models work in practice and how relevant stakeholders evaluate technologies within such frameworks. 

•             Teach MultiBiopsy how to assess whether a MedTech solution is suitable for a value-based care positioning, including how to identify relevant outcomes, economic drivers, and adoption incentives. 

•             Identify which stakeholders are most relevant in a value-based care framing, for example hospitals, integrated delivery networks, payers, provider groups, or innovation-oriented health systems. 

•             Clarify what outcomes, cost drivers, workflow improvements, and documentation elements are most important to establish if a value-based care strategy is to be credible. 

•             Support the company in understanding how to conduct structured research and documentation work related to value-based care, including how to organize findings and translate them into strategic conclusions. 

•             Develop a step-by-step plan describing how MultiBiopsy can explore, validate, and operationalize a value-based care market access pathway. 

•             Advise on which pilot dialogues, data generation activities, health economic work, and market tests should be prioritized. 

•             Support the company in distinguishing where value-based care complements traditional reimbursement and where it may provide a differentiated access route. 

•             Deliver a written strategy together with practical guidance, working methods, and one or more competence-building sessions that enable MultiBiopsy to continue this work internally.

 
4. TASK OBJECTIVES AND SUCCESS CRITERIA: 

The goal of the task is to give MultiBiopsy a realistic and actionable understanding of whether and how value-based care can become part of the company's market access model.

A satisfactory result should move the topic from a broad idea to a structured strategic option with clear logic, required evidence, stakeholder priorities, and concrete next steps. This also involves strengthen MultiBiopsy's internal competencies in how to assess value-based care opportunities, conduct structured research, document findings, and design practical strategies based on gathered insights.

Success criteria include:

•             A clear assessment is delivered of the relevance and potential role of value-based care for MultiBiopsy’s device and initial target market. 

•             The consultant help identify the most relevant stakeholder groups and explains how and why they influence decision-making within value-based care environments. 

•             The consultant provides structured guidance on how to research and evaluate value-based care opportunities, including how to identify relevant outcomes, cost drivers, and economic incentives. 

•             A concrete step-by-step roadmap is developed covering analysis, validation, evidence priorities, pilot opportunities, and strategic decision points. 

•             The final output explains how the value-based care option relates to and interacts with the reimbursement strategy rather than treating the two as isolated tracks. 

•             The team receives targeted knowledge transfer through working sessions or workshops, enabling internal use of the frameworks, methods, and documentation approaches after the consultancy ends. 

•             The team receives practical tools, templates, or structured approaches that support continued internal work with value-based care research, documentation, planning, and strategy development. 

•             The resulting strategy is practical, prioritized, and written in a form that can support future partner discussions, pilot planning, and investor communication.

5. BUDGET OG SPECIFICATION OF AN OFFER: 

MultiBiopsy requests a written offer for the advisory and competence-building task described above. The service must be limited to analysis, structured guidance, documentation support, strategic planning input, and competence development. Execution or implementation services beyond advisory and educational support are outside scope.

The expected total budget for this task is approximately 50,000 DKK, and bidders are requested to structure their proposal within this budget level.

The written offer should include:

Additional expectations for this tender:

•             Demonstrate experience with value-based care in the US, provider economics, or alternative market access models for MedTech.

•             Clarify which health system perspectives the bidder can cover, such as hospitals, IDNs, payers, bundled payments, or total-cost-of-care models.

•             Describe how the bidder will connect strategic analysis to concrete evidence and pilot planning.

•             Specify how the final roadmap will be structured and how MultiBiopsy will be involved throughout the process.

•             The bidder preferably has experience in working with start-ups outside the US. 

 
6. BACKGROUND FOR THE TENDER: 
Beyond Beta is subject to a number of requirements for good, healthy financial management, including documentation that the agreed price for external purchases is an expression of the market price. This tender is part of these requirements. 
We emphasize that the bidder must only make an offer on the requested task.  
Services of executing or implementing nature cannot be approved  
The winning bid is chosen based on an assessment of the best correlation between price and quality